We are live on !
Find out more
Peter Svennilson Portfolio holdings
AUM
$1.23B
Turnover
25%
1-Year Est. Return
301.34%
This Fund
S&P 500
This Quarter Est. Return
-6.34%
1 Year Est. Return
+301.34%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$162M
(+86%)
Cap. Flow
+$191M
Cap. Flow % of AUM
Cap. Flow %
54.54%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
1
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMDZ
Immune Design Corp.
IMDZ
|
+$38.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $230M | 65.66% |
+15,694,091
| New | +$230M |
2019 Q2
0 quarters
|
|
|
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $57.4M | 16.42% |
4,677,939
| – | – |
2018 Q4
2 quarters
|
|
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $34.6M | 9.88% |
3,102,934
| – | – |
2018 Q4
2 quarters
|
|
4
Arcus Biosciences
RCUS
$2.71B
| $28.2M | 8.04% |
3,540,850
| – | – |
2018 Q4
2 quarters
|
|
|
IMDZ
5
DELISTED
Immune Design Corp.
IMDZ
| – | – |
-6,642,942
| Closed | -$38.9M | – |
|
Similar funds
IA
Peter Svennilson's Q2 2019 Portfolio in Review
As of Q2 2019, Peter Svennilson held 5 positions worth $350M, up 86% from $188M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Peter Svennilson deployed $191M of net new capital in Q2 2019, opening 1 new position. Its largest new stake was NGM Biopharmaceuticals, Inc. Common Stock: 15,694,091 shares worth $230M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the most notable exit was Immune Design Corp., an estimated $38.9M sold.
- Peter Svennilson's largest Q2 2019 buy was NGM Biopharmaceuticals, Inc. Common Stock: 15,694,091 shares worth $230M.
- Peter Svennilson fully exited Immune Design Corp. in Q2 2019, selling an estimated $38.9M.
- Peter Svennilson's ten largest holdings make up 100% of its $350M portfolio in Q2 2019.
- Peter Svennilson opened 1 new position and closed 1 in Q2 2019.
- Peter Svennilson's portfolio value rose 86% quarter-over-quarter to $350M.
Based on Peter Svennilson's 13F filing for Q2 2019, filed 14 Aug 2019.